{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:11:19Z","timestamp":1792836679506,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41585-024-00953-0","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T15:07:09Z","timestamp":1731596829000},"page":"313-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["HSD3B1, prostate cancer mortality and modifiable outcomes"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4497-3923","authenticated-orcid":false,"given":"Pedro F. S.","family":"Freitas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-9927","authenticated-orcid":false,"given":"Alireza","family":"Abdshah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-7963","authenticated-orcid":false,"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1281-3474","authenticated-orcid":false,"given":"Nima","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"953_CR1","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1200\/JCO.23.00433","volume":"41","author":"C Dai","year":"2023","unstructured":"Dai, C., Dehm, S. M. & Sharifi, N. Targeting the androgen signaling axis in prostate cancer. J. Clin. Oncol. 41, 4267\u20134278 (2023).","journal-title":"J. Clin. Oncol."},{"key":"953_CR2","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1210\/me.2013-1007","volume":"27","author":"N Sharifi","year":"2013","unstructured":"Sharifi, N. Minireview: androgen metabolism in castration-resistant prostate cancer. Mol. Endocrinol. 27, 708\u2013714 (2013).","journal-title":"Mol. Endocrinol."},{"key":"953_CR3","doi-asserted-by":"publisher","first-page":"6351","DOI":"10.1158\/1078-0432.CCR-17-1313","volume":"23","author":"C Dai","year":"2017","unstructured":"Dai, C. et al. Direct metabolic interrogation of dihydrotestosterone biosynthesis from adrenal precursors in primary prostatectomy tissues. Clin. Cancer Res. 23, 6351\u20136362 (2017).","journal-title":"Clin. Cancer Res."},{"key":"953_CR4","doi-asserted-by":"publisher","first-page":"13728","DOI":"10.1073\/pnas.1107898108","volume":"108","author":"K-H Chang","year":"2011","unstructured":"Chang, K.-H. et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc. Natl Acad. Sci. USA 108, 13728\u201313733 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"953_CR5","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","volume":"68","author":"RB Montgomery","year":"2008","unstructured":"Montgomery, R. B. et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68, 4447\u20134454 (2008).","journal-title":"Cancer Res."},{"key":"953_CR6","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1210\/jcem-46-3-440","volume":"46","author":"J Geller","year":"1978","unstructured":"Geller, J. et al. DHT concentrations in human prostate cancer tissue. J. Clin. Endocrinol. Metab. 46, 440\u2013444 (1978).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"953_CR7","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1158\/1078-0432.CCR-05-0525","volume":"11","author":"MA Titus","year":"2005","unstructured":"Titus, M. A., Schell, M. J., Lih, F. B., Tomer, K. B. & Mohler, J. L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin. Cancer Res. 11, 4653\u20134657 (2005).","journal-title":"Clin. Cancer Res."},{"key":"953_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1146\/annurev-med-051418-060357","volume":"71","author":"RJ Auchus","year":"2020","unstructured":"Auchus, R. J. & Sharifi, N. Sex hormones and prostate cancer. Annu. Rev. Med. 71, 33\u201345 (2020).","journal-title":"Annu. Rev. Med."},{"key":"953_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/35094009","volume":"1","author":"BJ Feldman","year":"2001","unstructured":"Feldman, B. J. & Feldman, D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1, 34\u201345 (2001).","journal-title":"Nat. Rev. Cancer"},{"key":"953_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nrurol.2017.201","volume":"15","author":"D Hettel","year":"2018","unstructured":"Hettel, D. & Sharifi, N. HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer. Nat. Rev. Urol. 15, 191\u2013196 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"953_CR11","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","volume":"10","author":"M Hussain","year":"2024","unstructured":"Hussain, M. et al. Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review. JAMA Oncol. 10, 807\u2013820 (2024).","journal-title":"JAMA Oncol."},{"key":"953_CR12","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1210\/en.2019-00366","volume":"160","author":"N Sabharwal","year":"2019","unstructured":"Sabharwal, N. & Sharifi, N. HSD3B1 genotypes conferring adrenal-restrictive and adrenal-permissive phenotypes in prostate cancer and beyond. Endocrinology 160, 2180\u20132188 (2019).","journal-title":"Endocrinology"},{"key":"953_CR13","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl Acad. Sci. USA 116, 11428\u201311436 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"953_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1210\/er.2002-0050","volume":"26","author":"J Simard","year":"2005","unstructured":"Simard, J. et al. Molecular biology of the 3\u03b2-hydroxysteroid dehydrogenase\/\u03945-\u03944 isomerase gene family. Endocr. Rev. 26, 525\u2013582 (2005).","journal-title":"Endocr. Rev."},{"key":"953_CR15","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1210\/en.2010-0138","volume":"151","author":"K Evaul","year":"2010","unstructured":"Evaul, K., Li, R., Papari-Zareei, M., Auchus, R. J. & Sharifi, N. 3\u03b2-Hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. Endocrinology 151, 3514\u20133520 (2010).","journal-title":"Endocrinology"},{"key":"953_CR16","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.cell.2013.07.029","volume":"154","author":"KH Chang","year":"2013","unstructured":"Chang, K. H. et al. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 154, 1074\u20131084 (2013).","journal-title":"Cell"},{"key":"953_CR17","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/S1470-2045(16)30227-3","volume":"17","author":"JWD Hearn","year":"2016","unstructured":"Hearn, J. W. D. et al. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol. 17, 1435\u20131444 (2016).","journal-title":"Lancet Oncol."},{"key":"953_CR18","doi-asserted-by":"publisher","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-07-5997","volume":"68","author":"JA Locke","year":"2008","unstructured":"Locke, J. A. et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68, 6407\u20136415 (2008).","journal-title":"Cancer Res."},{"key":"953_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.urology.2020.08.028","volume":"145","author":"L Thomas","year":"2020","unstructured":"Thomas, L. & Sharifi, N. Germline HSD3B1 genetics and prostate cancer outcomes. Urology 145, 13\u201321 (2020).","journal-title":"Urology"},{"key":"953_CR20","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/bjc.2014.268","volume":"111","author":"K Chang","year":"2014","unstructured":"Chang, K., Ercole, C. & Sharifi, N. Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences. Br. J. Cancer 111, 1249\u20131254 (2014).","journal-title":"Br. J. Cancer"},{"key":"953_CR21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.clgc.2018.03.006","volume":"16","author":"AW Hahn","year":"2018","unstructured":"Hahn, A. W. et al. Germline variant in HSD3B1 (1245 A > C) and response to abiraterone acetate plus prednisone in men with new-onset metastatic castration-resistant prostate cancer. Clin. Genitourin. Cancer 16, 288\u2013292 (2018).","journal-title":"Clin. Genitourin. Cancer"},{"key":"953_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0115","volume":"2","author":"M Shiota","year":"2019","unstructured":"Shiota, M. et al. Association of missense polymorphism in HSD3B1 with outcomes among men with prostate cancer treated with androgen-deprivation therapy or abiraterone. JAMA Netw. Open 2, e190115 (2019).","journal-title":"JAMA Netw. Open"},{"key":"953_CR23","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.annonc.2020.06.006","volume":"31","author":"DJ Khalaf","year":"2020","unstructured":"Khalaf, D. J. et al. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies. Ann. Oncol. 31, 1186\u20131197 (2020).","journal-title":"Ann. Oncol."},{"key":"953_CR24","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.annonc.2020.06.009","volume":"31","author":"N Sharifi","year":"2020","unstructured":"Sharifi, N. Homozygous HSD3B1(1245C) inheritance and poor outcomes in metastatic castration-resistant prostate cancer with abiraterone or enzalutamide: what does it mean? Ann. Oncol. 31, 1103\u20131105 (2020).","journal-title":"Ann. Oncol."},{"key":"953_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/cam4.594","volume":"5","author":"E Varenhorst","year":"2016","unstructured":"Varenhorst, E. et al. Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases. Cancer Med. 5, 407\u2013414 (2016).","journal-title":"Cancer Med."},{"key":"953_CR26","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2017.0147","volume":"3","author":"N Agarwal","year":"2017","unstructured":"Agarwal, N. et al. Independent validation of effect of HSD3B1 genotype on response to androgen-deprivation therapy in prostate cancer. JAMA Oncol. 3, 856\u2013857 (2017).","journal-title":"JAMA Oncol."},{"key":"953_CR27","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/pros.22967","volume":"75","author":"G Wu","year":"2015","unstructured":"Wu, G. et al. Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer. Prostate 75, 777\u2013782 (2015).","journal-title":"Prostate"},{"key":"953_CR28","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1056\/NEJMms2029562","volume":"384","author":"LN Borrell","year":"2021","unstructured":"Borrell, L. N. et al. Race and genetic ancestry in medicine \u2014 a time for reckoning with racism. N. Engl. J. Med. 384, 474\u2013480 (2021).","journal-title":"N. Engl. J. Med."},{"key":"953_CR29","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1200\/OP.23.00040","volume":"19","author":"HY Hougen","year":"2023","unstructured":"Hougen, H. Y. et al. Disparities in diagnosis, treatment access, and time to treatment among Hispanic men with metastatic prostate cancer. JCO Oncol. Pract. 19, 645\u2013653 (2023).","journal-title":"JCO Oncol. Pract."},{"key":"953_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1200\/JCO.2024.42.4_suppl.84","volume":"42","author":"JW Moul","year":"2024","unstructured":"Moul, J. W. Real-world analyses of mortality risk after androgen deprivation therapy initiation in Black vs. White patients with prostate cancer. J. Clin. Oncol. 42, 84\u201384 (2024).","journal-title":"J. Clin. Oncol."},{"key":"953_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.15911","volume":"7","author":"KM Morgan","year":"2024","unstructured":"Morgan, K. M. et al. Androgen deprivation therapy and outcomes after radiation therapy in black patients with prostate cancer. JAMA Netw. Open 7, e2415911 (2024).","journal-title":"JAMA Netw. Open"},{"key":"953_CR32","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamaoncol.2017.3164","volume":"4","author":"JWD Hearn","year":"2018","unstructured":"Hearn, J. W. D. et al. Association of HSD3B1 genotype with response to androgen-deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer. JAMA Oncol. 4, 558\u2013562 (2018).","journal-title":"JAMA Oncol."},{"key":"953_CR33","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995\u20132005 (2011).","journal-title":"N. Engl. J. Med."},{"key":"953_CR34","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2012","unstructured":"Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138\u2013148 (2012).","journal-title":"N. Engl. J. Med."},{"key":"953_CR35","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187\u20131197 (2012).","journal-title":"N. Engl. J. Med."},{"key":"953_CR36","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer, T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424\u2013433 (2014).","journal-title":"N. Engl. J. Med."},{"key":"953_CR37","doi-asserted-by":"publisher","first-page":"938","DOI":"10.2310\/JIM.0b013e3181ff6bb8","volume":"58","author":"N Sharifi","year":"2010","unstructured":"Sharifi, N., McPhaul, M. J. & Auchus, R. J. \u201cGetting from here to there\u201d-mechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate cancer. J. Investig. Med. 58, 938\u2013944 (2010).","journal-title":"J. Investig. Med."},{"key":"953_CR38","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.tem.2020.05.006","volume":"31","author":"BD Naelitz","year":"2020","unstructured":"Naelitz, B. D. & Sharifi, N. Through the looking-glass: reevaluating DHEA metabolism through HSD3B1 genetics. Trends Endocrinol. Metab. 31, 680\u2013690 (2020).","journal-title":"Trends Endocrinol. Metab."},{"key":"953_CR39","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jamaoncol.2017.3159","volume":"4","author":"N Almassi","year":"2018","unstructured":"Almassi, N. et al. HSD3B1 and response to a nonsteroidal CYP17A1 inhibitor in castration-resistant prostate cancer. JAMA Oncol. 4, 554\u2013557 (2018).","journal-title":"JAMA Oncol."},{"key":"953_CR40","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nature14406","volume":"523","author":"Z Li","year":"2015","unstructured":"Li, Z. et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature 523, 347\u2013351 (2015).","journal-title":"Nature"},{"key":"953_CR41","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature17954","volume":"533","author":"Z Li","year":"2016","unstructured":"Li, Z. et al. Redirecting abiraterone metabolism to biochemically fine tune prostate cancer anti-androgen therapy. Nature 533, 547\u2013551 (2016).","journal-title":"Nature"},{"key":"953_CR42","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1172\/JCI98319","volume":"128","author":"M Alyamani","year":"2018","unstructured":"Alyamani, M. et al. HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. J. Clin. Invest. 128, 3333\u20133340 (2018).","journal-title":"J. Clin. Invest."},{"key":"953_CR43","doi-asserted-by":"publisher","first-page":"100608","DOI":"10.1016\/j.xcrm.2022.100608","volume":"3","author":"Z Mei","year":"2022","unstructured":"Mei, Z. et al. Management of prostate cancer by targeting 3\u03b2HSD1 after enzalutamide and abiraterone treatment. Cell Rep. Med. 3, 100608 (2022).","journal-title":"Cell Rep. Med."},{"key":"953_CR44","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.annonc.2020.04.473","volume":"31","author":"C Lu","year":"2020","unstructured":"Lu, C. et al. Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype. Ann. Oncol. 31, 1178\u20131185 (2020).","journal-title":"Ann. Oncol."},{"key":"953_CR45","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","volume":"20","author":"DJ Khalaf","year":"2019","unstructured":"Khalaf, D. J. et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 20, 1730\u20131739 (2019).","journal-title":"Lancet Oncol."},{"key":"953_CR46","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.18.00358","volume":"37","author":"E Castro","year":"2019","unstructured":"Castro, E. et al. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 37, 490\u2013503 (2019).","journal-title":"J. Clin. Oncol."},{"key":"953_CR47","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.6496","volume":"6","author":"JWD Hearn","year":"2020","unstructured":"Hearn, J. W. D. et al. HSD3B1 genotype and clinical outcomes in metastatic castration-sensitive prostate cancer. JAMA Oncol. 6, e196496 (2020).","journal-title":"JAMA Oncol."},{"key":"953_CR48","doi-asserted-by":"publisher","first-page":"101644","DOI":"10.1016\/j.xcrm.2024.101644","volume":"5","author":"N Sharifi","year":"2024","unstructured":"Sharifi, N. et al. HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy (ADT) and enzalutamide: (ARCHES). Cell Rep. Med. 5, 101644 (2024).","journal-title":"Cell Rep. Med."},{"key":"953_CR49","doi-asserted-by":"publisher","DOI":"10.1172\/JCI183583","volume":"134","author":"N Sharifi","year":"2024","unstructured":"Sharifi, N. et al. Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance. J. Clin. Invest. 134, e183583 (2024).","journal-title":"J. Clin. Invest."},{"key":"953_CR50","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737\u2013746 (2015).","journal-title":"N. Engl. J. Med."},{"key":"953_CR51","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.euo.2021.10.005","volume":"4","author":"K Van der Eecken","year":"2021","unstructured":"Van der Eecken, K. et al. Tissue- and blood-derived genomic biomarkers for metastatic hormone-sensitive prostate cancer: a systematic review. Eur. Urol. Oncol. 4, 914\u2013923 (2021).","journal-title":"Eur. Urol. Oncol."},{"key":"953_CR52","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong, A. J. et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 37, 2974\u20132986 (2019).","journal-title":"J. Clin. Oncol."},{"key":"953_CR53","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","volume":"24","author":"CJ Sweeney","year":"2023","unstructured":"Sweeney, C. J. et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 24, 323\u2013334 (2023).","journal-title":"Lancet Oncol."},{"key":"953_CR54","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.2976","volume":"7","author":"RR McKay","year":"2024","unstructured":"McKay, R. R. et al. Adrenal-permissive germline HSD3B1 allele and prostate cancer outcomes. JAMA Netw. Open 7, e242976 (2024).","journal-title":"JAMA Netw. Open"},{"key":"953_CR55","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.3402","volume":"7","author":"L Schiffer","year":"2024","unstructured":"Schiffer, L. & Sharifi, N. Adrenal-permissive HSD3B1 genotype-an invisible stimulator of prostate cancer mortality. JAMA Netw. Open 7, e243402 (2024).","journal-title":"JAMA Netw. Open"},{"key":"953_CR56","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","volume":"31","author":"E Castro","year":"2013","unstructured":"Castro, E. et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J. Clin. Oncol. 31, 1748\u20131757 (2013).","journal-title":"J. Clin. Oncol."},{"key":"953_CR57","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.42093","volume":"5","author":"M Marar","year":"2022","unstructured":"Marar, M. et al. Outcomes among African American and non-hispanic white men with metastatic castration-resistant prostate cancer with first-line abiraterone. JAMA Netw. Open 5, e2142093 (2022).","journal-title":"JAMA Netw. Open"},{"key":"953_CR58","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41391-021-00463-9","volume":"25","author":"DJ George","year":"2022","unstructured":"George, D. J. et al. Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 25, 524\u2013530 (2022).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"953_CR59","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jamaoncol.2019.0826","volume":"5","author":"RT Dess","year":"2019","unstructured":"Dess, R. T. et al. Association of black race with prostate cancer-specific and other-cause mortality. JAMA Oncol. 5, 975\u2013983 (2019).","journal-title":"JAMA Oncol."},{"key":"953_CR60","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.clgc.2021.07.008","volume":"20","author":"T Dorff","year":"2022","unstructured":"Dorff, T. et al. Prostate cancer characteristics and outcomes after prostatectomy in Asian-American men. Clin. Genitourin. Cancer 20, 92\u201392.e96 (2022).","journal-title":"Clin. Genitourin. Cancer"},{"key":"953_CR61","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/cncr.30503","volume":"123","author":"B Bernard","year":"2017","unstructured":"Bernard, B. et al. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer 123, 1536\u20131544 (2017).","journal-title":"Cancer"},{"key":"953_CR62","doi-asserted-by":"publisher","DOI":"10.1172\/JCI165718","volume":"133","author":"S Ganguly","year":"2023","unstructured":"Ganguly, S. et al. Intratumoral androgen biosynthesis associated with 3\u03b2-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer. J. Clin. Invest. 133, e165718 (2023).","journal-title":"J. Clin. Invest."},{"key":"953_CR63","doi-asserted-by":"publisher","DOI":"10.1172\/JCI183583","volume":"134","author":"N Sharifi","year":"2024","unstructured":"Sharifi, N. et al. Survival of men with metastatic hormone sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance. J. Clin. Invest. 134, e183583 (2024).","journal-title":"J. Clin. Invest."},{"key":"953_CR64","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163498","volume":"133","author":"X Li","year":"2023","unstructured":"Li, X. et al. BMX controls 3\u03b2HSD1 and sex steroid biosynthesis in cancer. J. Clin. Invest. 133, e163498 (2023).","journal-title":"J. Clin. Invest."},{"key":"953_CR65","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1158\/0008-5472.CAN-09-4610","volume":"70","author":"B Dai","year":"2010","unstructured":"Dai, B. et al. Compensatory upregulation of tyrosine kinase Etk\/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. Cancer Res. 70, 5587\u20135596 (2010).","journal-title":"Cancer Res."},{"key":"953_CR66","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1158\/0008-5472.CAN-17-3615","volume":"78","author":"S Chen","year":"2018","unstructured":"Chen, S. et al. BMX-mediated regulation of multiple tyrosine kinases contributes to castration resistance in prostate cancer. Cancer Res. 78, 5203\u20135215 (2018).","journal-title":"Cancer Res."},{"key":"953_CR67","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166499","volume":"133","author":"Y Qiu","year":"2023","unstructured":"Qiu, Y. A phosphorylation switch controls androgen biosynthesis in prostate cancer. J. Clin. Invest. 133, e166499 (2023).","journal-title":"J. Clin. Invest."},{"key":"953_CR68","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","volume":"15","author":"A Alu","year":"2022","unstructured":"Alu, A., Lei, H., Han, X., Wei, Y. & Wei, X. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. J. Hematol. Oncol. 15, 138 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"953_CR69","doi-asserted-by":"publisher","first-page":"eadi5798","DOI":"10.1126\/science.adi5798","volume":"383","author":"S Montoya","year":"2024","unstructured":"Montoya, S. et al. Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127. Science 383, eadi5798 (2024).","journal-title":"Science"},{"key":"953_CR70","doi-asserted-by":"publisher","first-page":"TPS5106","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5106","volume":"41","author":"RR McKay","year":"2023","unstructured":"McKay, R. R. et al. The Maverick trial: a phase 2 study of abivertinib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). J. Clin. Oncol. 41, TPS5106 (2023).","journal-title":"J. Clin. Oncol."},{"key":"953_CR71","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-24-0023","volume":"31","author":"M Shiota","year":"2024","unstructured":"Shiota, M. et al. Importance of 3\u03b2-hydroxysteroid dehydrogenases and their clinical use in prostate cancer. Endocr. Relat. Cancer 31, e240023 (2024).","journal-title":"Endocr. Relat. Cancer"}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00953-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00953-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00953-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T12:02:09Z","timestamp":1746705729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00953-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["953"],"URL":"https:\/\/doi.org\/10.1038\/s41585-024-00953-0","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,14]]},"assertion":[{"value":"3 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.S. is a co-inventor on patents related to HSD3B1 filed by his former employer, Cleveland Clinic. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}